Drug Targets and Molecular Basis of Drug Action
CSIR NET medicinal chemistry: enzymes, receptors, ion channels and DNA as drug targets, reversible and irreversible inhibition, agonists, Ki and IC50.
- 16 min
On this page · 15 sections
- Prerequisites
- The Hook: Why a Molecule of 350 Daltons Can Stop a Cell
- The Four Classical Target Families
- Binding: the Numbers You Must Be Able to Convert
- Enzyme Inhibitors: a Chemist’s Classification
- Receptors: Agonists, Antagonists and the Numbers
- Nucleic Acids as Targets
- Selectivity: the Only Thing That Makes a Drug Usable
- Memory Tricks
- Don’t Confuse
- Common Mistakes
- Practice
- Quick Revision Table
- Key Takeaways
- What’s Next
Prerequisites
- Michaelis–Menten kinetics, competitive and non-competitive inhibition: Enzyme Kinetics, Salt Effects and Catalysis.
- Non-covalent forces, protein folds and binding sites: Amino Acids, Peptides and Proteins and Enzymes: Catalysis, Kinetics and Regulation.
- Free energy and equilibrium constants: Thermodynamic Potentials and Maxwell Relations.
- Metal-based drugs, which this page refers to but does not repeat: Metal Complexes in Medicine.
The Hook: Why a Molecule of 350 Daltons Can Stop a Cell
The Four Classical Target Families
| Target | What the drug does | Representative classes |
|---|---|---|
| Enzymes | blocks catalysis (reversibly or covalently) | statins (HMG-CoA reductase), ACE inhibitors, sulfonamides, methotrexate, aspirin |
| Receptors | mimics or blocks the natural messenger | β-blockers, opioid analgesics, H\(_2\) antagonists, adrenergic agonists |
| Ion channels and transporters | blocks or modulates ion flux / uptake | local anaesthetics (Na\(^+\) channels), dihydropyridine Ca\(^{2+}\)-channel blockers, proton-pump inhibitors |
| Nucleic acids | alkylates, intercalates, cross-links or terminates chains | nitrogen mustards, cisplatin, anthracyclines, nucleoside analogues |
A fifth, structural, category matters in cancer and antiparasitic chemotherapy: tubulin, where one set of agents (vinca alkaloids, colchicine) blocks polymerisation and another (taxanes) stabilises the microtubule. Both stop mitosis, by opposite chemistry.
graph TD
A["Drug molecule"] --> B["Binds a macromolecule
(non-covalent complementarity)"]
B --> C["Enzyme: inhibition"]
B --> D["Receptor: agonism / antagonism"]
B --> E["Channel or transporter: block"]
B --> F["DNA / RNA: alkylation,
intercalation, chain termination"]
C --> G["Biological response
graded by occupancy"]
D --> G
E --> G
F --> GBinding: the Numbers You Must Be Able to Convert
For a reversible complex \( \mathrm{D} + \mathrm{R} \rightleftharpoons \mathrm{DR} \),
$$K_d = \frac{[\mathrm{D}][\mathrm{R}]}{[\mathrm{DR}]}, \qquad \text{fractional occupancy } \theta = \frac{[\mathrm{D}]}{K_d + [\mathrm{D}]}$$so \( K_d \) is the free concentration giving half occupancy, and
$$\Delta G^\circ = -RT\ln K_a = +RT\ln K_d$$Potency scales. p\(K_i\) = −log\(K_i\), pIC\(_{50}\) = −log IC\(_{50}\) (concentrations in mol L⁻¹). IC\(_{50}\) = 10 nM is pIC\(_{50}\) = 8.
IC50 is not Ki
IC\(_{50}\) is an assay number: it depends on how much substrate or radioligand is present. The Cheng–Prusoff relations convert it to a constant of the inhibitor:
$$\text{competitive enzyme inhibition:}\quad K_i = \frac{\mathrm{IC}_{50}}{1 + [\mathrm{S}]/K_M}; \qquad \text{radioligand displacement:}\quad K_i = \frac{\mathrm{IC}_{50}}{1 + [\mathrm{L}]/K_d}$$Run the assay at \( [\mathrm{S}] = K_M \) and IC\(_{50}\) is exactly \( 2K_i \). For an uncompetitive inhibitor the dependence runs the other way, and for a non-competitive inhibitor with \( \alpha = \alpha' \), IC\(_{50}\) = \( K_i \) at every \( [\mathrm{S}] \) — which is itself a diagnostic.
Enzyme Inhibitors: a Chemist’s Classification
Reversible
| Class | Binding | Kinetic signature (Lineweaver–Burk) | Example |
|---|---|---|---|
| Competitive | at the substrate site | lines meet on the \( 1/v \) axis; \( K_M \) apparent rises | methotrexate vs dihydrofolate (DHFR); sulfonamides vs PABA |
| Uncompetitive | to ES only | parallel lines | lithium on inositol monophosphatase (classical teaching example) |
| Non-competitive / mixed | to a second (allosteric) site | meet on the \( 1/[\mathrm{S}] \) axis, or off-axis | many allosteric modulators |
Transition-state analogues are the most potent reversible inhibitors, because an enzyme is by definition complementary to the transition state rather than to the substrate. Statins carry a dihydroxy-acid (or its lactone) that mimics the mevaldyl-type intermediate of HMG-CoA reductase; HIV protease inhibitors replace the scissile amide by a hydroxyethylene or hydroxyethylamine isostere, a non-hydrolysable stand-in for the tetrahedral intermediate; the transition-state idea also explains why phosphonates and boronic acids inhibit hydrolases so strongly.
Irreversible (covalent)
| Mode | Chemistry | Example |
|---|---|---|
| Affinity label / group-specific | an electrophile reacts with an active-site nucleophile after binding | aspirin acetylates a serine of cyclo-oxygenase |
| Strained-ring acylation | the ring opens on attack by the active-site nucleophile | β-lactams acylate the serine of the transpeptidase (PBP) |
| Mechanism-based (“suicide”) | the enzyme itself converts a latent group into the reactive species | 5-fluorouracil (as FdUMP) traps thymidylate synthase; allopurinol is oxidised by xanthine oxidase to oxypurinol, which stays bound |
| Acid-activated prodrug | chemistry generated at the site of action | omeprazole cyclises in acid to a sulfenamide that forms a disulfide with a cysteine of the gastric H\(^+\)/K\(^+\)-ATPase |
Kinetically, a covalent inhibitor shows time-dependent loss of activity, the apparent first-order rate constant saturating with inhibitor concentration (\( k_{\text{obs}} = k_{\text{inact}}[\mathrm{I}]/(K_I + [\mathrm{I}]) \)), and activity is not restored by dialysis. A merely tight-binding reversible inhibitor regains activity on dilution.
Receptors: Agonists, Antagonists and the Numbers
A receptor transduces binding into a cellular signal. The main families examined are G-protein-coupled receptors (seven transmembrane helices; adrenergic, muscarinic, opioid, histamine), ligand-gated ion channels (nicotinic acetylcholine, GABA\(_A\)), kinase-linked receptors and nuclear (steroid) receptors.
| Term | Meaning |
|---|---|
| Affinity | how tightly it binds (\( K_d \), \( K_i \)) |
| Efficacy | what the bound state does (0 for an antagonist, maximal for a full agonist) |
| Full agonist | produces the maximum tissue response |
| Partial agonist | binds well but gives a submaximal plateau; in the presence of a full agonist it behaves as an antagonist |
| Inverse agonist | reduces activity below the constitutive baseline |
| Competitive antagonist | shifts the agonist curve right in parallel, \( E_{\max} \) unchanged |
| Non-competitive / irreversible antagonist | depresses \( E_{\max} \) |
EC\(_{50}\) is the concentration giving half the maximal response; it equals \( K_d \) only when occupancy and response are proportional. Tissues with “spare receptors” give EC\(_{50} \ll K_d \).
Schild analysis
For a competitive antagonist B, the dose ratio \( r \) (the factor by which the agonist concentration must be raised to restore the original response) obeys
$$r - 1 = \frac{[\mathrm{B}]}{K_B}, \qquad \log(r - 1) = \log[\mathrm{B}] - \log K_B$$A plot of \( \log(r-1) \) against \( \log[\mathrm{B}] \) is linear with slope 1 for simple competitive antagonism, and its intercept on the \( \log[\mathrm{B}] \) axis is \( \log K_B \); p\(A_2\) = \( -\log K_B \). A slope differing from unity signals something other than simple competition.
Nucleic Acids as Targets
| Mode | Chemistry | Examples |
|---|---|---|
| Alkylation | aziridinium or similar electrophile attacks N7 of guanine; bifunctional agents cross-link the two strands | nitrogen mustards, nitrosoureas, busulfan |
| Coordination cross-link | square-planar Pt(II) binds two adjacent N7 guanines | cisplatin and its analogues (see Metal Complexes in Medicine) |
| Intercalation | a flat polycyclic aromatic slots between base pairs, unwinding the helix; often with topoisomerase poisoning | anthracyclines, acridines |
| Groove binding | crescent-shaped molecules read the minor groove | netropsin-type oligoamides |
| Chain termination | a nucleoside analogue lacking a 3′-OH (or with it blocked) is incorporated and stops extension | zidovudine (3′-azido), acyclovir (acyclic, no 3′-OH) |
| Enzyme of nucleic-acid metabolism | the target is an enzyme, with DNA damage downstream | quinolones (DNA gyrase/topoisomerase IV), rifamycins (bacterial RNA polymerase) |
Nucleoside antivirals illustrate selectivity beautifully: acyclovir is phosphorylated to the monophosphate essentially only by the virus-encoded thymidine kinase, host kinases complete the triphosphate, and the viral DNA polymerase then incorporates it. A drug that is inert until a viral enzyme activates it is intrinsically selective.
Selectivity: the Only Thing That Makes a Drug Usable
Selective toxicity (Ehrlich’s idea of a “magic bullet”) is achieved by:
- A target the host does not have — bacterial cell-wall transpeptidase (β-lactams), bacterial 70S ribosome (tetracyclines, macrolides, aminoglycosides), viral reverse transcriptase or protease.
- A target the host has in a different form — bacterial dihydrofolate reductase binds trimethoprim far more tightly than the human enzyme does; the human pathway also differs in that we take up folate rather than synthesise it, which is why sulfonamides (dihydropteroate synthase inhibitors) are selective at all.
- Differential uptake or activation — prodrugs activated by a pathogen or tumour enzyme.
- Subtype selectivity — β\(_1\)- versus β\(_2\)-adrenoceptors, COX-1 versus COX-2, kinase selectivity profiles.
The therapeutic index, TD\(_{50}\)/ED\(_{50}\) (or LD\(_{50}\)/ED\(_{50}\) in animals), quantifies the margin between effect and harm; it is large for penicillins and small for cytotoxic anticancer drugs, which is exactly why one is given casually and the other is not.
Memory Tricks
Don’t Confuse
| This | vs | That |
|---|---|---|
| \( K_i \) (constant of the inhibitor) | IC\(_{50}\) (depends on \( [\mathrm{S}] \) or \( [\mathrm{L}] \) in the assay) | |
| \( K_d \) (binding) | EC\(_{50}\) (response); equal only without receptor reserve or signal amplification | |
| Affinity | Efficacy — an antagonist can have very high affinity and zero efficacy | |
| Competitive antagonist (parallel right shift, \( E_{\max} \) kept) | Irreversible antagonist (\( E_{\max} \) depressed) | |
| Transition-state analogue (reversible, very tight) | Suicide substrate (covalent, time-dependent) | |
| Antimetabolite (resembles a metabolite, blocks its pathway) | Antagonist (blocks a receptor) | |
| Potency (concentration needed) | Efficacy (height of the plateau) | |
| Therapeutic index TD\(_{50}\)/ED\(_{50}\) | Selectivity ratio between two targets |
Common Mistakes
Practice
All questions below are original practice questions written for this page. They are not from any CSIR NET paper.
Level 1: Foundation
- Write the Cheng–Prusoff relation for a competitive enzyme inhibitor.
- What does a Schild plot of slope 1 indicate?
- Name the kinetic observation that distinguishes a mechanism-based inhibitor from a competitive one.
Answers
- \( K_i = \mathrm{IC}_{50}/(1 + [\mathrm{S}]/K_M) \).
- Simple competitive antagonism; the \( \log[\mathrm{B}] \) intercept gives \( \log K_B \).
- Time-dependent, saturable loss of activity that is not reversed by dialysis or dilution.
Level 2: Part B Style
Practice Q1. An inhibitor gives IC\(_{50}\) = 90 nM in an assay run at \( [\mathrm{S}] = 2K_M \). If the inhibition is competitive, \( K_i \) is:
(a) 30 nM (b) 45 nM (c) 90 nM (d) 270 nM
Answer: (a) 30 nM
\( K_i = 90/(1 + 2) = 30 \) nM. Option (b) uses \( 1 + [\mathrm{S}]/K_M = 2 \) (i.e. \( [\mathrm{S}] = K_M \)); option (d) multiplies instead of dividing.
Practice Q2. A compound binds its receptor with \( K_d = 1.0 \times 10^{-8} \) mol L⁻¹ at 298 K. The standard free energy of binding is closest to:
(a) −27 kJ mol⁻¹ (b) −46 kJ mol⁻¹ (c) −57 kJ mol⁻¹ (d) +46 kJ mol⁻¹
Answer: (b) −46 kJ mol⁻¹
\( \Delta G^\circ = RT\ln K_d = 8.314 \times 298.15 \times \ln(10^{-8}) = -45.7 \) kJ mol⁻¹. Option (c) corresponds to \( K_d = 10^{-10} \); option (d) has the sign of \( \ln K_a \) reversed.
Practice Q3. Which pairing is incorrect?
(a) Sulfonamide — dihydropteroate synthase (b) Methotrexate — dihydrofolate reductase (c) β-Lactam — bacterial transpeptidase (d) Acyclovir — bacterial 30S ribosomal subunit
Answer: (d)
Acyclovir is a guanosine analogue activated by viral thymidine kinase and acting as a DNA chain terminator at the viral DNA polymerase. The 30S subunit is the target of aminoglycosides and tetracyclines.
Practice Q4. In the presence of a fixed concentration of an antagonist, the agonist dose–response curve is shifted to the right in parallel with no change in maximum response. The antagonist is:
(a) competitive and reversible (b) irreversible (c) an inverse agonist (d) a partial agonist
Answer: (a)
Parallel right shift with \( E_{\max} \) preserved is the signature of surmountable, competitive antagonism. An irreversible antagonist depresses \( E_{\max} \); a partial agonist caps the plateau below the full agonist maximum.
Level 3: Part C Style
Practice Q5. An inhibitor of a serine hydrolase shows: (i) no inhibition when added at the moment of assay, but near-complete inhibition after 20 min pre-incubation; (ii) \( k_{\text{obs}} \) that rises with \( [\mathrm{I}] \) and saturates; (iii) no recovery of activity after exhaustive dialysis; (iv) complete protection by saturating substrate during pre-incubation. Which statements are correct?
- The inhibitor forms a covalent adduct.
- Binding occurs at the active site before the covalent step.
- The data are consistent with a reversible competitive inhibitor of very low \( K_i \).
- Saturation of \( k_{\text{obs}} \) implies a non-covalent complex precedes inactivation.
(a) 1, 2 and 4 only (b) 1 and 3 only (c) 2, 3 and 4 only (d) 1, 2, 3 and 4
Answer: (a) 1, 2 and 4 only
- Time dependence plus failure to recover on dialysis. Correct.
- Substrate protection localises the event to the active site. Correct.
- A reversible inhibitor, however tight, recovers on dialysis and inhibits immediately. Wrong.
- Saturation kinetics (\( k_{\text{obs}} = k_{\text{inact}}[\mathrm{I}]/(K_I + [\mathrm{I}]) \)) require a pre-formed EI complex. Correct.
Practice Q6. A competitive antagonist is tested at three concentrations; the agonist dose ratios \( r \) are:
| \( [\mathrm{B}] \) / mol L⁻¹ | \( 1.0\times10^{-8} \) | \( 1.0\times10^{-7} \) | \( 1.0\times10^{-6} \) |
|---|---|---|---|
| \( r \) | 2.0 | 11 | 101 |
Which statements are correct?
- The Schild plot has unit slope.
- \( K_B = 1.0 \times 10^{-8} \) mol L⁻¹.
- p\(A_2\) = 8.
- At \( [\mathrm{B}] = 1.0 \times 10^{-5} \) mol L⁻¹ the predicted dose ratio is about 1001.
(a) 1 and 2 only (b) 1, 2, 3 and 4 (c) 2, 3 and 4 only (d) 1 and 4 only
Answer: (b) 1, 2, 3 and 4
\( r - 1 \) = 1.0, 10, 100 — exactly proportional to \( [\mathrm{B}] \), so the plot of \( \log(r-1) \) against \( \log[\mathrm{B}] \) has slope 1. \( K_B = [\mathrm{B}]/(r-1) = 10^{-8} \) at every point, so p\(A_2\) = 8 (the concentration giving \( r = 2 \) is indeed \( 10^{-8} \)). Extrapolating, \( r - 1 = 10^{-5}/10^{-8} = 1000 \). All four correct.
Practice Q7. Two inhibitors of the same enzyme are compared at 298 K: A has \( K_i = 1.0 \) µM, B has \( K_i = 1.0 \) nM. Which statements are correct?
- B binds about 17 kJ mol⁻¹ more tightly than A.
- The difference corresponds to three orders of magnitude in \( K_i \).
- If B is a transition-state analogue and A a substrate analogue, the result is expected.
- B must act covalently.
(a) 1, 2 and 3 only (b) 2 and 4 only (c) 1, 2, 3 and 4 (d) 3 and 4 only
Answer: (a) 1, 2 and 3 only
- \( \Delta\Delta G = RT\ln(10^3) = 3 \times 5.71 = 17.1 \) kJ mol⁻¹. Correct.
- From µM to nM is \( 10^3 \). Correct.
- Enzymes are complementary to the transition state, so its analogues bind far more tightly than substrate analogues. Correct.
- Nanomolar affinity says nothing about covalency. Wrong.
Quick Revision Table
| Idea | Formula / fact |
|---|---|
| Occupancy | \( \theta = [\mathrm{D}]/(K_d + [\mathrm{D}]) \) |
| Free energy | \( \Delta G^\circ = RT\ln K_d \); one log unit = 5.7 kJ mol⁻¹ (298 K) |
| Cheng–Prusoff (enzyme) | \( K_i = \mathrm{IC}_{50}/(1 + [\mathrm{S}]/K_M) \) |
| Cheng–Prusoff (radioligand) | \( K_i = \mathrm{IC}_{50}/(1 + [\mathrm{L}]/K_d) \) |
| Schild | \( r - 1 = [\mathrm{B}]/K_B \); slope 1; p\(A_2 = -\log K_B \) |
| Covalent inhibition | \( k_{\text{obs}} = k_{\text{inact}}[\mathrm{I}]/(K_I + [\mathrm{I}]) \); time-dependent, non-dialysable |
| Transition-state analogue | tightest reversible binders; HIV protease hydroxyethylene isostere |
| Suicide substrate | activated by the target enzyme (5-FU → FdUMP; allopurinol → oxypurinol) |
| Chain terminators | no free 3′-OH: zidovudine, acyclovir |
| Selectivity | absent target, different target, different activation, different subtype |
| Therapeutic index | TD\(_{50}\)/ED\(_{50}\) |
Key Takeaways
What’s Next
- Physicochemical Properties, SAR and QSAR: how structural change is turned into predictable change in potency.
- Drug Metabolism, Prodrugs and Pharmacokinetics: what the body does to the molecule.
- Major Drug Classes and Their Chemistry: the classes named above, with their structural chemistry.
- Medicinal Chemistry: Quick Revision.